Abstracts tagged "osteoporosis"

Abstract Number: 0353 • ACR Convergence 2025
Incidence of Clinical Fragility Fractures and Mortality in Patients with Rheumatoid Arthritis Treated with Rituximab
Montserrat Roig Kim¹, Carla Marco-Pascual², Martí Aguilar-Coll¹, Javier Narváez³, Joan Miquel Nolla¹ and Carmen Gomez Vaquero⁴, ¹Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, Spain, ²Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, ³Hospital Universitario de Bellvitge, Barcelona, Spain, ⁴Hospital Universitari de Bellvitge, ⁰⁸⁹⁰⁷ L'Hospitalet, Spain
Background/Purpose: Patients with Rheumatoid Arthritis (RA) have an increased risk of osteoporosis and fragility fractures. Bone loss in RA is multifactorial and mainly determined by…
Abstract Number: 0162 • ACR Convergence 2025
Clinical Relevance of Systematic Comorbidity Screening in Autoimmune and Inflammatory Diseases
Martin Michaud, Caroline Arlet, Jean Alain Bournazeau, François de Maupeou, Julie Gaston, Stephanie Mermet, Helene Coulier, Marie Oustalet, Christophe Raspaud, Cédric Maurice, Sophie Recipon, Claire Verplancken, Kim Paricaud and Leonardo Astudillo, Clinique Saint Exupery, TOULOUSE, France
Background/Purpose: Chronic autoimmune and inflammatory diseases are associated with an increased prevalence of various comorbidities, which may impact both prognosis and therapeutic strategies. EULAR recommends…
Abstract Number: 2594 • ACR Convergence 2025
Comparing Immunogenicity Between TVB-009 and Reference Denosumab in Healthy Adults and Participants with Postmenopausal Osteoporosis
Karel Pavelka¹, Frank Schneider², Deepak S³, Bracha Timan⁴, Hadas Barkay⁴ and Anton Buchner², ¹Institute of Rheumatology and Department of Rheumatology, ¹st Faculty of Medicine, Charles University, Prague, Czech Republic, Prague, Czech Republic, ²Teva GmbH, Ulm, Germany, ³Teva Pharma India Private Limited, Bangalore, India, ⁴Teva Pharmaceutical Industries Ltd., Netanya, Israel
Background/Purpose: TVB-009 is being developed as a proposed biosimilar candidate to the reference denosumab. Denosumab is a human IgG2 monoclonal antibody that binds to the…
Abstract Number: 2108 • ACR Convergence 2025
Multidisciplinary Fragility Fracture Management Across Two Coordinated Hospitals: Evaluating Risk Factors, Treatment Approaches, and Long-Term Patient Outcomes in Those With and Without Prior Fractures
César Antonio Egües Dubuc¹, Nerea Alcorta Lorenzo², Esther Laso Lucas³, Carlos Maria Lizasoain Alustiza⁴, Claudia Murillo Erazo³, Gabriela Jimenez Clemente³, Gaspar de La Herran Nuñez⁴, Vicente Lavilla Garcia³, Imanol Gabarain Morcillo⁴, Leire Unanue Pumar⁴, Irene Corcuera Elosegui⁴, Antonio Martin Garcia⁴, Jorge Jesus Cancio Fanlo⁵, Maria Ariztia Sarratea³, Ander Alberdi Arbelaiz⁴, Iñaki Maria Arruabarrena Echeverria³, Elena Zubillaga Azpiroz⁴ and LUIS LOPEZ DOMINGUEZ⁶, ¹Donostia University Hospital, San Sebastián, Pais Vasco, Spain, ²University Hospital Donostia, san sebastian, Spain, ³Matia Hospital, San Sebastian, Pais Vasco, Spain, ⁴Donostia University Hospital, San Sebastian, Pais Vasco, Spain, ⁵Donostia University Hospital, San Sebastian, ⁶Hospital Universitario Donostia, San Sebastian, Spain
Background/Purpose: Our Fracture Coordination Unit operates across two hospitals: University Hospital of Donostia (UHD) and Matía Hospital (MH). Patients with a geriatric profile are transferred…
Abstract Number: 0352 • ACR Convergence 2025
Complication Rates of Typical Hip Fractures, Subtrochanteric Femoral Fractures, and Atypical Femoral Fractures
Marshall Weber¹, William Obremskey², Jared Huling³, Nitya Shah³, Emily Budde⁴, Zhiping Huo⁴, Reside Jacob⁴, Brinda Basida¹, Colton Hoffer¹, Binni Makkar⁵ and Laura Carbone¹, ¹Augusta University, Augusta, GA, ²Vanderbilt University, Nashville, TN, ³University of Minnesota School of Public Health, Minneapolis, MN, ⁴Center of Innovation for Complex Chronic Healthcare, Washington DC, DC, ⁵University of Kentucky, Lexington, KY
Background/Purpose: Atypical femoral fractures (AFFs) are a rare complication of bisphosphonate use and a major reason that drug holidays are recommended following bisphosphonate use. However,…
Abstract Number: 0149 • ACR Convergence 2025
Effect Of Osteoporosis And Opioid Use On Mortality And Unplanned Healthcare Utilization Among Patients With Rheumatoid Arthritis
Viengneesee Thao, Molly Moore Jeffery, Nafisseh Warner and Elena myasoedova, Mayo Clinic, Rochester, MN
Background/Purpose: Patients with rheumatoid arthritis (RA) have a 2-fold increase in risk for osteoporosis compared to the general population. About 30-50% of RA patients experience…
Abstract Number: 2592 • ACR Convergence 2025
Romosozumab and Denosumab Combination Therapy in Postmenopausal Osteoporosis
Giovanni Adami¹, Francesco Pollastri², Angelo Fassio², Camilla Benini², Davide Gatti², Ombretta Viapiana² and Maurizio Rossini², ¹University of Verona, Italy, Verona, Italy, ²University of Verona, Verona, Italy
Background/Purpose: Transition from long-term denosumab to PTH-analogs or romosozumab might expose patients to the risk of the so-called rebound phenomenon. Adding romosozumab to denosumab might…
Abstract Number: 2107 • ACR Convergence 2025
Experience of a Fragility Fracture Coordination Unit Integrated Across Two Hospitals: An Innovative Multidisciplinary Model for Optimizing the Management of Geriatric and Non-Geriatric Patients Beyond Surgery After an Osteoporotic Bone Fragility Fracture
César Antonio Egües Dubuc¹, Esther Laso Lucas², Nerea Alcorta Lorenzo³, Carlos Maria Lizasoain Alustiza⁴, Leire Unanue Pumar⁴, Gabriela Jimenez Clemente², Claudia Murillo Erazo², Vicente Lavilla Garcia², Ander Alberdi Arbelaiz⁴, Elena Zubillaga Azpiroz⁴, Imanol Gabarain Morcillo⁴, Jorge Jesus Cancio Fanlo⁵, Maria Ariztia Sarratea², Iñaki Maria Arruabarrena Echeverria⁴, Gaspar de La Herran Nuñez⁴, Antonio Martin Garcia⁴ and LUIS LOPEZ DOMINGUEZ⁶, ¹Donostia University Hospital, San Sebastián, Pais Vasco, Spain, ²Matia Hospital, San Sebastian, Pais Vasco, Spain, ³University Hospital Donostia, san sebastian, Spain, ⁴Donostia University Hospital, San Sebastian, Pais Vasco, Spain, ⁵Donostia University Hospital, San Sebastian, ⁶Hospital Universitario Donostia, San Sebastian, Spain
Background/Purpose: Fracture Coordination Units typically function within a single hospital using a multidisciplinary approach. Our unit, established in February 2024, pioneers a model coordinating care…
Abstract Number: 0350 • ACR Convergence 2025
Perioperative Evaluation of Blood Tests Including Bone Turnover Markers in Patients Undergoing Surgery for Proximal Femur Fractures
KEN NAKASEKO, KUWANA CITY MEDICAL CENTER, KUWANA, Mie, Japan
Background/Purpose: Osteoporosis treatment is essential to prevent fractures. However, few patients with proximal femur fractures receive osteoporosis treatment before injury. Initiating treatment postoperatively is critical…
Abstract Number: 0064 • ACR Convergence 2025
Sclerostin from marrow adipogenic precursors is essential for bone and joint homeostasis in mice
Tailin He and Yifang Mei, Shenzhen Third People's Hospital, Shenzhen, China (People's Republic)
Background/Purpose: A novel mesenchymal subpopulation known as 'marrow adipogenic lineage precursors' (MALPs) has been identified, characterized by the expression of various adipocyte markers while lacking…
Abstract Number: 1297 • ACR Convergence 2024
Assessment of Knowledge of Osteoporosis Among Female Nursing Students and Staff Nurses in an Urban Medical College in India
Varsha Bhatt¹ and Sri lakshmi Sathiyaseelan², ¹Bharati Vidyapeeth University Medical College and Hospital, Pune, Maharashtra, India, ²Bharati Vidyapeeth medical college and hospital, chennai, Tamil Nadu, India
Background/Purpose: Osteoporosis is one of the most common metabolic bone disorders and is associated with an increased risk of fracture.[1] Data suggests that 20% of…
Abstract Number: 2128 • ACR Convergence 2024
Trabecular Bone Score Curve from a Qatari Population, Data from Qatar Biobank
Omar Alsaed¹, Hans Didier² and Samar Alemadi³, ¹Hamad Medical Corporation, Doha, Qatar, ²Lausanne University Hospital, Lausanne, Switzerland, ³Hamad medical corporation, Doha, Qatar
Background/Purpose: Trabecular bone score (TBS iNsight™) is an advanced imaging software application for bone densitometers (DXA). TBS gives an assessment of bone architecture by estimating…
Abstract Number: 2147 • ACR Convergence 2024
Primary and Secondary Prevention of Osteoporotic Fracture in the Elderly Patients
Belén Miguel Ibáñez¹, Carmen Pablos Hernández², Marta Ibáñez Martínez¹, Carolina Cristina Chacón Vélez³, Laura Blanco Ramis³, Sergio Cimadevila Santiago¹, Olga Martínez González³, Ana Isabel Turrión Nieves³, Manuel Cipriano Martín Martínez³, Cristina Hidalgo Calleja¹, Carlos Montilla Morales¹, Olga Compán Fernández³, Lourdes Lorenzo Rodríguez¹, José Vicente Hernández Madrid¹, Susana Gómez Castro³, Juan Francisco Blanco Blanco⁴ and Alfonso González Ramírez², ¹University Healthcare Complex of Salamanca, Rheumatology, Salamanca, Spain, ²University Healthcare Complex of Salamanca, Geriatric, Salamanca, Spain, ³University Healthcare Complex of Salamanca, Rheumatology, Salamanca, Castilla y Leon, Spain, ⁴University Healthcare Complex of Salamanca Traumatology, Salamanca, Spain
Background/Purpose: Osteoporosis is a common disease of the elderly patient. It is often under-diagnosed and is known with the onset of fragility fracture. Furthermore, despite…
Abstract Number: 0143 • ACR Convergence 2024
Behavioral Factors and Chronic Conditions Associated with Rheumatoid Arthritis, KNHANES 2010 to 2021
GI HYUN MYUNG and Juwon Lim, Seoul National University Hospital, Seoul, Republic of Korea
Background/Purpose: Rheumatoid arthritis (RA) is associated with multiple genetic and environmental factors. In terms of environmental, dietary and lifestyle factors, there have been discrepancies on…
Abstract Number: 1405 • ACR Convergence 2024
Perceived Healthcare Discrimination Among Individuals with Musculoskeletal Conditions: A Retrospective Cross-Sectional Analysis
Titilayo Adeniran¹, Bertilia Trieu², Sandra Goldsmith¹ and Laura Robbins¹, ¹Hospital for Special Surgery (HSS), New York, NY, ²Hospital for Special Surgery, New York, NY
Background/Purpose: Musculoskeletal conditions, including osteoarthritis (OA), osteoporosis (OP), rheumatoid arthritis (RA), and chronic pain, significantly burden individuals' health and well-being. These conditions often lead to…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].